Get startedLog in
    Picture of ORYZON Genomics SA logo

    ORY — ORYZON Genomics SA News Story

    0.000.00%
    es flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Brief: Oryzon Presents Preliminary Data From Ongoing Phase Ib Frida Trial

    Picture of ORYZON Genomics SA logoORYZON Genomics SA
    14/06/2024 13:07
    June 14 (Reuters) - Oryzon Genomics SA  ORY.MC :
    * ORYZON PRESENTS PRELIMINARY DATA FROM ONGOING PHASE IB
FRIDA
TRIAL WITH IADADEMSTAT PLUS GILTERITINIB IN RELAPSED/REFRACTORY
FLT3-MUT AML PATIENTS AT EHA-2024
    * DATA FROM FIRST TWO COHORTS DEMONSTRATED THAT COMBINATION
OF
IADADEMSTAT PLUS GILTERITINIB WAS SAFE AND SHOWED STRONG
ANTILEUKEMIC ACTIVITY
    * : THIRD COHORT IS ONGOING FOLLOWING FDA'S OPTIMUS GUIDANCE

Source text for Eikon:  ID:nGNX3hQglh 
Further company coverage:  ORY.MC 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on ORYZON Genomics SA

    See all news